ETC-206
10mM in DMSO
- Product Code: 181290
CAS:
1464151-33-4
| Molecular Weight: | 408.45 g./mol | Molecular Formula: | C₂₅H₂₀N₄O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
ETC-206 is a potent and selective inhibitor of ALK (anaplastic lymphoma kinase), primarily investigated for its use in the treatment of non-small cell lung cancer (NSCLC) that harbors ALK gene rearrangements. It is designed to target both ALK fusion proteins and resistant mutants that emerge after treatment with earlier-generation ALK inhibitors. Due to its ability to cross the blood-brain barrier effectively, ETC-206 shows strong activity against brain metastases, a common complication in ALK-positive NSCLC patients. Its development focuses on overcoming resistance mutations such as G1202R and F1174L, making it a candidate for patients who have progressed on other ALK-directed therapies. Preclinical studies indicate high selectivity and sustained target inhibition, supporting its evaluation in clinical trials for advanced solid tumors, especially those driven by ALK alterations.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿4,800.00 |
+
-
|
ETC-206
ETC-206 is a potent and selective inhibitor of ALK (anaplastic lymphoma kinase), primarily investigated for its use in the treatment of non-small cell lung cancer (NSCLC) that harbors ALK gene rearrangements. It is designed to target both ALK fusion proteins and resistant mutants that emerge after treatment with earlier-generation ALK inhibitors. Due to its ability to cross the blood-brain barrier effectively, ETC-206 shows strong activity against brain metastases, a common complication in ALK-positive NSCLC patients. Its development focuses on overcoming resistance mutations such as G1202R and F1174L, making it a candidate for patients who have progressed on other ALK-directed therapies. Preclinical studies indicate high selectivity and sustained target inhibition, supporting its evaluation in clinical trials for advanced solid tumors, especially those driven by ALK alterations.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :